Fundoiano-Hershcovitz Yifat, Hirsch Abigail, Dar Sharon, Feniger Eitan, Goldstein Pavel
DarioHealth, Caesarea, Israel.
School of Public Health, University of Haifa, Haifa, Israel.
JMIR Diabetes. 2021 Feb 18;6(1):e24030. doi: 10.2196/24030.
The use of remote data capture for monitoring blood glucose and supporting digital apps is becoming the norm in diabetes care. One common goal of such apps is to increase user awareness and engagement with their day-to-day health-related behaviors (digital engagement) in order to improve diabetes outcomes. However, we lack a deep understanding of the complicated association between digital engagement and diabetes outcomes.
This study investigated the association between digital engagement (operationalized as tagging of behaviors alongside glucose measurements) and the monthly average blood glucose level in persons with type 2 diabetes during the first year of managing their diabetes with a digital chronic disease management platform. We hypothesize that during the first 6 months, blood glucose levels will drop faster and further in patients with increased digital engagement and that difference in outcomes will persist for the remainder of the year. Finally, we hypothesize that disaggregated between- and within-person variabilities in digital engagement will predict individual-level changes in blood glucose levels.
This retrospective real-world analysis followed 998 people with type 2 diabetes who regularly tracked their blood glucose levels with the Dario digital therapeutics platform for chronic diseases. Subjects included "nontaggers" (users who rarely or never used app features to notice and track mealtime, food, exercise, mood, and location, n=585) and "taggers" (users who used these features, n=413) representing increased digital engagement. Within- and between-person variabilities in tagging behavior were disaggregated to reveal the association between tagging behavior and blood glucose levels. The associations between an individual's tagging behavior in a given month and the monthly average blood glucose level in the following month were analyzed for quasicausal effects. A generalized mixed piecewise statistical framework was applied throughout.
Analysis revealed significant improvement in the monthly average blood glucose level during the first 6 months (t=-10.01, P<.001), which was maintained during the following 6 months (t=-1.54, P=.12). Moreover, taggers demonstrated a significantly steeper improvement in the initial period relative to nontaggers (t=2.15, P=.03). Additional findings included a within-user quasicausal nonlinear link between tagging behavior and glucose control improvement with a 1-month lag. More specifically, increased tagging behavior in any given month resulted in a 43% improvement in glucose levels in the next month up to a person-specific average in tagging intensity (t=-11.02, P<.001). Above that within-person mean level of digital engagement, glucose levels remained stable but did not show additional improvement with increased tagging (t=0.82, P=.41). When assessed alongside within-person effects, between-person changes in tagging behavior were not associated with changes in monthly average glucose levels (t=1.30, P=.20).
This study sheds light on the source of the association between user engagement with a diabetes tracking app and the clinical condition, highlighting the importance of within-person changes versus between-person differences. Our findings underscore the need for and provide a basis for a personalized approach to digital health.
利用远程数据采集来监测血糖并支持数字应用程序,正逐渐成为糖尿病护理的常态。这类应用程序的一个共同目标是提高用户对日常健康相关行为的认知度和参与度(数字参与度),以改善糖尿病治疗效果。然而,我们对数字参与度与糖尿病治疗效果之间复杂的关联缺乏深入了解。
本研究调查了数字参与度(通过在血糖测量的同时标记行为来衡量)与2型糖尿病患者在使用数字慢性病管理平台管理糖尿病的第一年中的每月平均血糖水平之间的关联。我们假设,在最初6个月内,数字参与度较高的患者血糖水平下降得更快、幅度更大,并且这种结果差异将在当年剩余时间持续存在。最后,我们假设数字参与度在个体间和个体内的差异将预测血糖水平的个体变化。
这项回顾性真实世界分析跟踪了998名使用达里奥慢性病数字治疗平台定期监测血糖水平的2型糖尿病患者。受试者包括“非标记者”(很少或从不使用应用程序功能来记录和跟踪用餐时间\食物\运动\情绪和位置的用户,n = 585)和“标记者”(使用这些功能的用户,n = 413),后者代表更高的数字参与度。对标记行为在个体内和个体间的差异进行分析,以揭示标记行为与血糖水平之间的关联。分析了个体在给定月份的标记行为与次月每月平均血糖水平之间的关联,以确定准因果效应。整个过程采用广义混合分段统计框架。
分析显示,最初6个月每月平均血糖水平有显著改善(t = -10.01,P <.001),在随后6个月保持稳定(t = -1.54,P =.12)。此外,与非标记者相比,标记者在初始阶段的改善更为显著(t = 2.15,P =.03)。其他发现包括标记行为与血糖控制改善之间存在个体内准因果非线性联系,且有1个月的延迟。更具体地说,在任何给定月份标记行为增加,会导致次月血糖水平改善43%,直至达到个体特定的标记强度平均值(t = -11.02,P <.001)。超过该个体内数字参与度平均水平后,血糖水平保持稳定,但标记行为增加并未带来额外改善(t = 0.82,P =.41)。与个体内效应一起评估时,个体间标记行为的变化与每月平均血糖水平的变化无关(t = 1.30,P =.20)。
本研究揭示了用户参与糖尿病跟踪应用程序与临床状况之间关联的来源,强调了个体内变化相对于个体间差异的重要性。我们的研究结果强调了个性化数字健康方法的必要性,并为其提供了依据。